Alpha Cognition Inc. Effective Income Tax Rate Reconciliation, Other Adjustments, Percent
Alpha Cognition Inc. (ACOG) reported Effective Income Tax Rate Reconciliation, Other Adjustments, Percent of -9.20% for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments · last filed 2026-03-31
- Alpha Cognition Inc. effective income tax rate reconciliation, other adjustments, percent for fiscal 2024 was -9.20%, a 264.29% decline from fiscal 2023.
- Alpha Cognition Inc. effective income tax rate reconciliation, other adjustments, percent for fiscal 2023 was 5.60%.
| Period end | Effective Income Tax Rate Reconciliation, Other Adjustments, Percent 6 month | Effective Income Tax Rate Reconciliation, Other Adjustments, Percent 9 month | Effective Income Tax Rate Reconciliation, Other Adjustments, Percent 12 month | Effective Income Tax Rate Reconciliation, Other Adjustments, Percent 12 month as first filed |
|---|---|---|---|---|
| 2024-12-31 | -9.20% 10-K · filed 2026-03-31 | 17.90% 10-K · filed 2025-03-31 | ||
| 2024-09-30 | 50.00% 10-Q · filed 2024-11-14 | |||
| 2024-06-30 | 50.00% 10-Q · filed 2024-08-12 | |||
| 2023-12-31 | 5.60% 10-K · filed 2025-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |